TY  - JOUR
AU  - Pérez-Ramírez, Cristina
AU  - Cañadas-Garre, Marisa
AU  - Molina, Miguel Ángel
AU  - Cabeza Barrera, José
AU  - Faus-Dáder, María José
PY  - 2019
DO  - 10.1016/j.mrrev.2019.04.001
UR  - http://hdl.handle.net/10668/14398
T2  - Mutation research. Reviews in mutation research
AB  - EGFR tyrosine kinase inhibitors (EGFR-TKIs) are the treatment of choice for advanced-stage (IIIB-IV) NSCLC patients with mutations in EGFR. However, EGFR-TKIs clinical outcomes vary from person to person and these inter-individual differences may be...
LA  - en
KW  - EGFR tyrosine kinase inhibitors
KW  - Non-small cell lung cancer
KW  - Polymorphisms
KW  - Response
KW  - Survival
KW  - Toxicity
KW  - Carcinoma, Non-Small-Cell Lung
KW  - ErbB Receptors
KW  - Humans
KW  - Lung Neoplasms
KW  - Polymorphism, Single Nucleotide
KW  - Protein Kinase Inhibitors
TI  - Impact of single nucleotide polymorphisms on the efficacy and toxicity of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients.
TY  - research article
VL  - 781
ER  -